nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

07.03.2021 | Original Article

Long COVID hallmarks on [18F]FDG-PET/CT: a case-control study

verfasst von: Martina Sollini, Silvia Morbelli, Michele Ciccarelli, Maurizio Cecconi, Alessio Aghemo, Paola Morelli, Silvia Chiola, Fabrizia Gelardi, Arturo Chiti

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The present study hypothesised that whole-body [18F]FDG-PET/CT might provide insight into the pathophysiology of long COVID.

Methods

We prospectively enrolled 13 adult long COVID patients who complained for at least one persistent symptom for >30 days after infection recovery. A group of 26 melanoma patients with negative PET/CT matched for sex/age was used as controls (2:1 control to case ratio). Qualitative and semi-quantitative analysis of whole-body images was performed. Fisher exact and Mann-Whitney tests were applied to test differences between the two groups. Voxel-based analysis was performed to compare brain metabolism in cases and controls. Cases were further grouped according to prevalent symptoms and analysed accordingly.

Results

In 4/13 long COVID patients, CT images showed lung abnormalities presenting mild [18F]FDG uptake. Many healthy organs/parenchyma SUVs and SUV ratios significantly differed between the two groups (p ≤ 0.05). Long COVID patients exhibited brain hypometabolism in the right parahippocampal gyrus and thalamus (uncorrected p < 0.001 at voxel level). Specific area(s) of hypometabolism characterised patients with persistent anosmia/ageusia, fatigue, and vascular uptake (uncorrected p < 0.005 at voxel level).

Conclusion

[18F]FDG PET/CT acknowledged the multi-organ nature of long COVID, supporting the hypothesis of underlying systemic inflammation. Whole-body images showed increased [18F]FDG uptake in several “target” and “non-target” tissues. We found a typical pattern of brain hypometabolism associated with persistent complaints at the PET time, suggesting a different temporal sequence for brain and whole-body inflammatory changes. This evidence underlined the potential value of whole-body [18F]FDG PET in disclosing the pathophysiology of long COVID.

Nur mit Berechtigung zugänglich

Treglia G. Diagnostic performance of 18F-FDG PET/CT in infectious and inflammatory diseases according to published meta-analyses. Contrast Media Mol Imaging. Hindawi Ltd. and John Wiley and Sons, Inc.; 2019;2019:3018349.

Qin C, Liu F, Yen TC, Lan X. 18F-FDG PET/CT findings of COVID-19: a series of four highly suspected cases. Eur J Nucl Med Mol Imaging. 2020.

Annunziata S, Delgado Bolton RC, Kamani CH, Prior JO, Albano D, Bertagna F, et al. Role of 2-[18f]fdg as a radiopharmaceutical for pet/ct in patients with covid-19: a systematic review. Pharmaceuticals. 2020.

Living with Covid19. 2020.

Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. British Medical Journal Publishing Group; 2020;370:m3026.

The Lancet. Facing up to long COVID. Lancet. 2020.

Meeting the challenge of long COVID. Nat Med. 2020;26:1803.

Delorme C, Paccoud O, Kas A, Hesters A, Bombois S, Shambrook P, et al. COVID-19-related encephalopathy: a case series with brain FDG-positron-emission tomography/computed tomography findings. Eur J Neurol Eur J Neurol. 2020;27:2651–7.CrossRef

Guedj E, Million M, Dudouet P, Tissot-Dupont H, Bregeon F, Cammilleri S, et al. 18F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders? Eur J Nucl Med Mol Imaging. Eur J Nucl Med Mol Imaging. 2020.

10.

Kas A, Soret M, Pyatigoskaya N, Habert M-O, Hesters A, Le Guennec L, et al. The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. Eur J Nucl Med Mol Imaging. Eur J Nucl Med Mol Imaging. 2021.

11.

Guedj E, Campion JY, Dudouet P, Kaphan E, Bregeon F, Tissot-Dupont H, et al. 18F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. Springer; 2021;1–11.

12.

Ling Y, Xu S-B, Lin Y-X, Tian D, Zhu Z-Q, Dai F-H, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl). 2020;133:1039–43.CrossRef

13.

Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20:e276–88.CrossRef

14.

Morris SB, Schwartz NG, Patel P, Abbo L, Beauchamps L, Balan S, et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection — United Kingdom and United States, March–August 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1450–6.CrossRef

15.

Maiese A, Manetti AC, La Russa R, Di Paolo M, Turillazzi E, Frati P, et al. Autopsy findings in COVID-19-related deaths: a literature review. Forensic Sci Med Pathol. 2020.

16.

Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ, et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med. 2013;54:647–58.CrossRef

17.

Love C, Tomas MB, Tronco GG, Palestro CJ. FDG PET of infection and inflammation. RadioGraphics. 2005;25:1357–68.CrossRef

18.

Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2014:42, 328–354.

19.

Sollini M, Ciccarelli M, Cecconi M, Aghemo A, Morelli P, Gelardi F, et al. Vasculitis changes in COVID-19 survivors with persistent symptoms: an [¹⁸F]FDG-PET/CT study. Eur J Nucl Med Mol Imaging. 2020.

20.

Slart RHJA. FDG-PET/CT(a) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol ImagingSpringer. 2018;45:1250–69.CrossRef

21.

Huang YC, Hsu CC, Huang P, Yin TK, Chiu NT, Wang PW, et al. The changes in brain metabolism in people with activated brown adipose tissue: a PET study. Neuroimage. 2011.

22.

Hua C, Merchant TE, Li X, Li Y, Shulkin BL. Establishing age-associated normative ranges of the cerebral 18F-FDG uptake ratio in children. J Nucl Med. 2015;56:575–9.CrossRef

23.

Friston KJ, Holmes AP, Worsley KJ, Poline J-P, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp. 1994;2:189–210.CrossRef

24.

Della Rosa PA, Cerami C, Gallivanone F, Prestia A, Caroli A, Castiglioni I, et al. A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics. 2014;12:575–93.CrossRef

25.

Hajian-Tilaki K. Sample size estimation in diagnostic test studies of biomedical informatics. J Biomed Inform. Elsevier Inc.; 2014;48:193–204.

26.

Lieberman MD, Cunningham WA. Type I and type II error concerns in fMRI research: re-balancing the scale. Soc Cogn Affect Neurosci. 2009;4:423–8.CrossRef

27.

Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020;41:3038–44.CrossRef

28.

Karimi-Galougahi M, Yousefi-Koma A, Bakhshayeshkaram M, Raad N, Haseli S. 18FDG PET/CT scan reveals hypoactive orbitofrontal cortex in anosmia of COVID-19. Acad Radiol. 2020;27:1042–3.CrossRef

29.

Ances BM, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin A, Houghton DJ, et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain. 2005;128:1764–77.CrossRef

30.

Marini C, Morbelli S, Cistaro A, Campi C, Caponnetto C, Bauckneht M, et al. Interplay between spinal cord and cerebral cortex metabolism in amyotrophic lateral sclerosis. Brain. 2018;141:2272–9.CrossRef

31.

Bai Y, Xu J, Chen L, Fu C, Kang Y, Zhang W, et al. Inflammatory response in lungs and extrapulmonary sites detected by [18F] fluorodeoxyglucose PET/CT in convalescing COVID-19 patients tested negative for coronavirus. Eur J Nucl Med Mol Imaging. Eur J Nucl Med Mol Imaging. 2021.

32.

Chefer S, Thomasson D, Seidel J, Reba RC, Bohannon JK, Lackemeyer MG, et al. Modeling [18F]-FDG lymphoid tissue kinetics to characterize nonhuman primate immune response to Middle East respiratory syndrome-coronavirus aerosol challenge. EJNMMI Res. 2015;5:65.CrossRef

33.

Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis Nature Publishing Group. 2020;50:54–67.CrossRef

34.

Becker RC. COVID-19-associated vasculitis and vasculopathy. J Thromb Thrombolysis Springer. 2020:1–13.

35.

Pijl JP, Kwee TC, Slart RHJA, Yakar D, Wouthuyzen-Bakker M, Glaudemans AWJM. Clinical implications of increased uptake in bone marrow and spleen on FDG-PET in patients with bacteremia. Eur J Nucl Med Mol Imaging. 2020.

36.

Bahce I, Vos CG, Dickhoff C, Hartemink KJ, Dahele M, Smit EF, et al. Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLC. Lung Cancer. 2014;85:205–12.CrossRef

37.

Kazama T, Swanston N, Podoloff DA, Macapinlac HA. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging. 2005;32:1406–11.CrossRef

38.

Dyall J, Johnson RF, Chefer S, Leyson C, Thomasson D, Seidel J, et al. [18F]-Fluorodeoxyglucose uptake in lymphoid tissue serves as a predictor of disease outcome in the nonhuman primate model of monkeypox virus infection. McFadden G, editor. J Virol. 2017;91.

39.

Stephen G. Baum M. Adult multisystem inflammatory syndrome associated with COVID-19. NEJM J Watch; 2020;2020.

40.

Xiang YT, Yu X, Ungvari GS, Correll CU, Chiu HFK. Outcomes of SARS survivors in China: not only physical and psychiatric co-morbidities. East Asian Arch Psychiatr. 2014;24:37–8.

41.

Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018.

42.

Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App. medRxiv. Cold Spring Harbor Laboratory Press; 2020;2020.10.19.20214494.

Titel: Long COVID hallmarks on [18F]FDG-PET/CT: a case-control study
verfasst von: Martina Sollini
Silvia Morbelli
Michele Ciccarelli
Maurizio Cecconi
Alessio Aghemo
Paola Morelli
Silvia Chiola
Fabrizia Gelardi
Arturo Chiti
Publikationsdatum: 07.03.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2021
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05294-3

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Long COVID hallmarks on [18F]FDG-PET/CT: a case-control study

Abstract

Purpose

Methods

Results

Conclusion

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2021

Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors

Equivalent tumor detection for early and late FAPI-46 PET acquisition

Complicated pubovesical fistula on PET/CT and MRI

[68Ga]Ga-PSMA-HBED-CC PET/CT demonstrates to be superior to ceCT in detecting early treatment response in metastatic clear cell renal cell carcinoma

A head-to-head comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study

18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer